



PATENT
Docket No. 235.0020 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant(s): Tarleton et al.) Group Art Unit: 1645 AUG 02 2001
Serial No.: 09/518,156) Examiner: I. Field TECH CENTER 1600 2900
Filed: March 2, 2000)

For: PROPHYLACTIC AND THERAPEUTIC IMMUNIZATION AGAINST
PROTOZOAN INFECTION AND DISEASE

**RESPONSE TO RESTRICTION REQUIREMENT,
COMMUNICATION REGARDING ENTRY OF SEQUENCE LISTING,
AND PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents
Washington D.C. 20231

Dear Sir:

Please amend the above-identified application as follows:

In the Specification

Please replace the paragraph beginning at page 5, line 14 through line 16, with the following rewritten paragraph. Pursuant to 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

Pharmaceutical compositions containing immunogenic polypeptides or polynucleotides encoding immunogenic polypeptides together with a pharmaceutical carrier are also provided.

Please replace the paragraph beginning at page 20, line 7 through line 26, with the following rewritten paragraph. Pursuant to 37 C.F.R. §1.121, this paragraph is also shown in Appendix A with notations to indicate the changes made.

An immunogenic polypeptide for use in a *T. cruzi* vaccine according to the invention can be one that is expressed by *T. cruzi* in the extracellular (trypomastigote) stage, in the intracellular (amastigote) stage, or during both stages of the life cycle. Preferably, the immunogenic polypeptide is expressed by a *T. cruzi* amastigote; more preferably, it is expressed by the amastigote in the early stage of infection, within about 24 hours from initial infection. Also preferably, the immunogenic polypeptide is a membrane surface-associated polypeptide or a